Nanoparticles for multimodal in vivo imaging in nanomedicine

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 711-726

  Key, Jaehong ^a,b   Leary, James F ^a,b,c  

^a PURDUE UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

^c PURDUE UNIVERSITY   (United States)

Author keywords

Cancer; CT; MRI; Multimodal imaging; Nanomedicine; Nanoparticles; NIRF; PET

Indexed keywords

CANCER; CT; MRI; MULTIMODAL IMAGING; NANOMEDICINE; NANOPARTICLES; NIRF; PET;

ANIMALS; CONTRAST MEDIA; HUMANS; IMAGE ENHANCEMENT; MULTIMODAL IMAGING; NANOMEDICINE; NANOPARTICLES; SURGERY, COMPUTER-ASSISTED;

EID: 84893320082     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S53717     Document Type: Review

References (93)

1. van Dam GM, Themelis G, Crane LM, et al. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results. Nat Med. 2011;17(10):1315-1319.
2. Leary JF. Nanotechnology: what is it and why is small so big? Can J Ophthalmol. 2010;45(5):449-456.
3. Weissleder R, Pittet MJ. Imaging in the era of molecular oncology. Nature. 2008;452(7187):580-589.
4. Hahn M, Singh A, Sharma P, Brown S, Moudgil B. Nanoparticles as contrast agents for in vivo bioimaging: current status and future perspectives. Anal Bioanal Chem. 2011;399(1):3-27.
5. Cheon J, Lee JH. Synergistically integrated nanoparticles as multimodal probes for nanobiotechnology. Acc Chem Res. 2008;41(12): 1630-1640.
6. Kim JH, Park K, Nam HY, Lee S, Kim K, Kwon IC. Polymers for bioimaging. Prog Polym Sci. 2007;32(8-9):1031-1053.
7. Caravan P. Strategies for increasing the sensitivity of gadolinium based MRI contrast agents. Chem Soc Rev. 2006;35(6):512-523.
8. Abujudeh HH, Kaewlai R, Kagan A, et al. Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients. Radiology. 2009 2009;253(1):81-89.
9. Thomsen H. Gadolinium-based contrast media may be nephrotoxic even at approved doses. Eur Radiol. 2004;14(9):1654-1656.
10. Na HB, Song IC, Hyeon T. Inorganic nanoparticles for MRI contrast agents. Adv Mater. 2009;21(21):2133-2148.
11. Aryal S, Key J, Stigliano C, Ananta JS, Zhong M, Decuzzi P. Engineered magnetic hybrid nanoparticles with enhanced relaxivity for tumor imaging. Biomaterials. 2013;34(31):7725-7732.
12. Park J, An K, Hwang Y, et al. Ultra-large-scale syntheses of monodisperse nanocrystals. Nat Mater. 2004;3(12):891-895.
13. Lee JH, Jang JT, Choi JS, et al. Exchange-coupled magnetic nanoparticles for efficient heat induction. Nat Nanotechnol. 2011;6(7):418-422.
14. Duguet E, Vasseur S, Mornet S, Devoisselle JM. Magnetic nanoparticles and their applications in medicine. Nanomedicine (Lond). 2006;1(2):157-168.
15. Cunningham CH, Arai T, Yang PC, McConnell MV, Pauly JM, Conolly SM. Positive contrast magnetic resonance imaging of cells labeled with magnetic nanoparticles. Magn Reson Med. 2005;53(5):999-1005.
16. Kim YB, Bae KH, Yoo SS, Park TG, Park H. Positive contrast visualization for cellular magnetic resonance imaging using susceptibility-weighted echo-time encoding. Magn Reson Imaging. 2009;27(5):601-610.
17. Zhu H, Jones CK, van Zijl PCM, Barker PB, Zhou J. Fast 3D chemical exchange saturation transfer (CEST) imaging of the human brain. Magn Reson Med. 2010;64(3):638-644.
18. Day S, Kettunen M, Gallagher F, et al. Detecting tumor response to treatment using hyperpolarized 13C magnetic resonance imaging and spectroscopy. Nat Med. 2007;13(11):1382-1387.
19. Gallagher F, Kettunen M, Day S, et al. Magnetic resonance imaging of pH in vivo using hyperpolarized 13C-labelled bicarbonate. Nature. 2008;453(7197):940-943.
20. Lee JH, Huh YM, Jun YW, et al. Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging. Nat Med. 2007;13(1):95-99.
21. Lee N, Kim H, Choi SH, et al. Magnetosome-like ferrimagnetic iron oxide nanocubes for highly sensitive MRI of single cells and transplanted pancreatic islets. Proc Natl Acad Sci U S A. 2011;108(7):2662-2667.
22. 2 relaxivity for highly sensitive in vivo MRI of tumors. Nano Lett. 2012;12(6):3127-3131.
23. Key J, Dhawan D, Knapp DW, et al. Multimodal in vivo MRI and NIRF imaging of bladder tumor using peptide conjugated glycol chitosan nanoparticles. Proc SPIE. 2012;8225.
24. Brasch RC. Rationale and applications for macromolecular Gd-based contrast agents. Magn Reson Med. 1991;22(2):282-287.
25. Adam G, Neuerburg J, Spuntrup E, Mühler A, Scherer K, Günther RW. Gd-DTPA-cascade-polymer: potential blood pool contrast agent for MR imaging. J Magn Reson Imaging. 1994;4(3):462-466.
26. Roberts HC, Saeed M, Roberts TP, et al. Comparison of albumin (Gd-DTPA) 30 and Gd-DTPA-24-cascade-polymer for measurements of normal and abnormal microvascular permeability. J Magn Reson Imaging. 1997;7(2):331-338.
27. Orang-Khadivi K, Pierce BL, Ollom CM, Floyd LJ, Siegle RL, Williams RF. New magnetic resonance imaging techniques for the detection of breast cancer. Breast Cancer Res Treat. 1994;32(1):119-135.
28. Wiener EC, Brechbiel MW, Brothers H, et al. Dendrimer-based metal chelates: a new class of magnetic resonance imaging contrast agents. Magn Reson Med. 1994;31(1):1-8.
29. Reimer P, Balzer T. Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications. Eur Radiol. 2003;13(6):1266-1276.
30. Jung CW, Jacobs P. Physical and chemical properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. Magn Reson Imaging. 1995;13(5):661-674.
31. Reimer P, Tombach B. Hepatic MRI with SPIO: detection and characterization of focal liver lesions. Eur Radiol. 1998;8(7):1198-1204.
32. Bulte JW, Brooks RA, Moskowitz BM, Bryant LH, Frank JA. Relaxometry and magnetometry of the MR contrast agent MION-46L. Magn Reson Med. 1999;42(2):379-384.
33. Bogdanov AA Jr, Martin C, Weissleder R, Brady TJ. Trapping of dextran-coated colloids in liposomes by transient binding to aminophospholipid: preparation of ferrosomes. Biochim Biophys Acta. 1994;1193(1):212-218.
34. Bulte JWM, Md C, Despres D, Frank JA. Preparation, relaxometry, and biokinetics of PEGylated magnetoliposomes as MR contrast agent. J Magn Magn Mater. 1999;194(1-3):204-209.
35. Brenner DJ, Elliston CD, Hall EJ, Berdon WE. Estimated risks of radiation-induced fatal cancer from pediatric CT. AJR Am J Roentgenol. 2001;176(2):289-296.
36. Seltzer SM, Berger MJ. Bremsstrahlung spectra from electron interactions with screened atomic nuclei and orbital electrons. Nucl Instrum Methods Phys Res B. 1985;12(1):95-134.
37. Pietsch H. CT contrast agents. In: Kiessling F, Pichler BJ, editors. Heidelberg: Springer; 2011:141-149.
38. Kong WH, Lee WJ, Cui ZY, et al. Nanoparticulate carrier containing water-insoluble iodinated oil as a multifunctional contrast agent for computed tomography imaging. Biomaterials. 2007;28(36):5555-5561.
39. Elrod DB, Partha R, Danila D, Casscells SW, Conyers JL. An iodinated liposomal computed tomographic contrast agent prepared from a diiodophosphatidylcholine lipid. Nanomedicine. 2009;5(1):42-45.
40. Skajaa T, Cormode DP, Falk E, Mulder WJM, Fisher EA, Fayad ZA. Highdensity lipoprotein-based contrast agents for multimodal imaging of atherosclerosis. Arterioscler Thromb Vasc Biol. 2010;30(2): 169-176.
41. Aviv H, Bartling S, Kieslling F, Margel S. Radiopaque iodinated copolymeric nanoparticles for X-ray imaging applications. Biomaterials. 2009;30(29):5610-5616.
42. Rabin O, Manuel Perez J, Grimm J, Wojtkiewicz G, Weissleder R. An X-ray computed tomography imaging agent based on long-circulating bismuth sulphide nanoparticles. Nat Mater. 2006;5(2):118-122.
43. Kim D, Yu MK, Lee TS, Park JJ, Jeong YY, Jon S. Amphiphilic polymer-coated hybrid nanoparticles as CT/MRI dual contrast agents. Nanotechnology. 2011;22(15):155101.
44. Kim D, Park S, Lee JH, Jeong YY, Jon S. Antibiofouling polymercoated gold nanoparticles as a contrast agent for in vivo X-ray computed tomography imaging. J Am Chem Soc. 2007;129(24):7661-7665.
45. Jackson PA, Rahman WN, Wong CJ, Ackerly T, Geso M. Potential dependent superiority of gold nanoparticles in comparison to iodinated contrast agents. Eur J Radiol. 2010;75(1):104-109.
46. Popovtzer R, Agrawal A, Kotov NA, et al. Targeted gold nanoparticles enable molecular CT imaging of cancer. Nano Lett. 2008;8(12): 4593-4596.
47. Cai QY, Kim SH, Choi KS, et al. Colloidal gold nanoparticles as a blood-pool contrast agent for X-ray computed tomography in mice. Invest Radiol. 2007;42(12):797-806.
48. Massoud TF, Gambhir SS. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev. 2003;17(5):545-580.
49. Rosenthal MS, Cullom J, Hawkins W, Moore SC, Tsui BMW, Yester M. Quantitative SPECT imaging: a review and recommendations by the Focus Committee of the Society of Nuclear Medicine Computer and Instrumentation Council. J Nucl Med. 1995;36(8):1489-1513.
50. Strijckmans K. The isochronous cyclotron: principles and recent developments. Comput Med Imaging Graph. 2001;25(2):69-78.
51. Ye Y, Chen X. Integrin targeting for tumor optical imaging. Theranostics. 2011;1:102-126.
52. Kim K, Kim JH, Park H, et al. Tumor-homing multifunctional nanoparticles for cancer theragnosis: simultaneous diagnosis, drug delivery, and therapeutic monitoring. J Control Release. 2010;146(2):219-227.
53. Lin TY, Zhang H, Wang S, et al. Targeting canine bladder transitional cell carcinoma with a human bladder cancer-specific ligand. Mol Cancer. 2011;10(1):9.
54. Licha K, Olbrich C. Optical imaging in drug discovery and diagnostic applications. Adv Drug Deliv Rev. 2005;57(8):1087-1108.
55. Ntziachristos V, Chance B. Breast imaging technology: probing physiology and molecular function using optical imaging: applications to breast cancer. Breast Cancer Res. 2000;3(1):41-46.
56. Michalet X, Pinaud FF, Bentolila LA, et al. Quantum dots for live cells, in vivo imaging, and diagnostics. Science. 2005;307(5709):538-544.
57. Janczewski D, Zhang Y, Das GK, et al. Bimodal magnetic-fluorescent probes for bioimaging. Microsc Res Tech. 2011;74(7):563-576.
58. Wang F, Banerjee D, Liu Y, Chen X, Liu X. Upconversion nanoparticles in biological labeling, imaging, and therapy. Analyst. 2010;135(8):1839-1854.
59. 2 core/shell nanoparticles and the applications for in vivo NIR detection. Adv Mater. 2008;20(21):4118-4123.
60. 3+ nanocrystals. Nano Res. 2010;3(5):317-325.
61. Melancon MP, Wang Y, Wen X, et al. Development of a macromolecular dual-modality MR-optical imaging for sentinel lymph node mapping. Invest Radiol. 2007;42(8):569-578.
62. Knapp DW, Adams LG, DeGrand AM, et al. Sentinel lymph node mapping of invasive urinary bladder cancer in animal models using invisible light. Eur Urol. 2007;52(6):1700-1709.
63. Swierczewska M, Lee S, Chen X. Inorganic nanoparticles for multimodal molecular imaging. Mol Imaging. 2011;10(1):3-16.
64. Lee DE, Koo H, Sun IC, Ryu JH, Kim K, Kwon IC. Multifunctional nanoparticles for multimodal imaging and theragnosis. Chem Soc Rev. 2012;41(7):2656-2672.
65. Louie A. Multimodality imaging probes: design and challenges. Chem Rev. 2010;110(5):3146-3195.
66. Pichler BJ, Judenhofer MS, Pfannenberg C. Multimodal imaging approaches: PET/CT and PET/MRI. Handb Exp Pharmacol. 2008; (185 Pt 1):109-132.
67. Judenhofer MS, Wehrl HF, Newport DF, et al. Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nat Med. 2008;14(4):459-465.
68. Nam T, Park S, Lee SY, et al. Tumor targeting chitosan nanoparticles for dual-modality optical/MR cancer imaging. Bioconjug Chem. 2010;21(4):578-582.
69. Nguyen QT, Olson ES, Aguilera TA, et al. Surgery with molecular fluorescence imaging using activatable cell-penetrating peptides decreases residual cancer and improves survival. Proc Natl Acad Sci U S A. 2010;107(9):4317-4322.
70. Key J, Kim K, Dhawan D, et al. Dual-modality in vivo imaging for MRI detection of tumors and NIRF-guided surgery using multi-component nanoparticles. Vol: Proc SPIE. 2011;79087:90805.
71. Key J, Cooper C, Kim A, et al. In vivo NIRF and MR dual-modality imaging using glycol chitosan nanoparticles. J Control Release. 2012;163(2):249-255.
72. Yu Y, Sun D. Superparamagnetic iron oxide nanoparticle theranostics for multimodality tumor imaging, gene delivery, targeted drug and prodrug delivery. Expert Rev Clin Pharmacol. 2010;3 (1):117-130.
73. Maeda H. Tumor-Selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug Chem. 2010;21(5):797-802.
74. Chen K, Xie J, Xu H, et al. Triblock copolymer coated iron oxide nanoparticle conjugate for tumor integrin targeting. Biomaterials. 2009;30(36):6912-6919.
75. Tan YF, Chandrasekharan P, Maity D, et al. Multimodal tumor imaging by iron oxides and quantum dots formulated in poly (lactic acid)-dalpha-tocopheryl polyethylene glycol 1000 succinate nanoparticles. Biomaterials. 2011;32(11):2969-2978.
76. Zhou J, Sun Y, Du X, Xiong L, Hu H, Li F. Dual-modality in vivo imaging using rare-earth nanocrystals with near-infrared to near-infrared (NIR-to-NIR) upconversion luminescence and magnetic resonance properties. Biomaterials. 2010;31(12):3287-95.
77. xS core-shell nanoparticles for dual-modal imaging and photothermal therapy. J Am Chem Soc. 2013;135(23):8571-8577.
78. 2 core-shell nanocubes: novel bimodal contrast agents for MRI and optical imaging. Sci Rep. 2013;3:2647.
79. 64Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging. Biomaterials. 2011;32(17):4151-4160.
80. 64Cu(II)-bis(dithiocarbamatebisphosphonate) and its conjugation with superparamagnetic iron oxide nanoparticles: in vivo evaluation as dual-modality PET-MRI agent. Angew Chem Int Ed Engl. 2011;50(24):5509-5513.
81. 99m)Tc-bisphosphonate-iron oxide nanoparticle conjugates for dual-modality biomedical imaging. Bioconjug Chem. 2011;22(3):455-465.
82. Choi JS, Park JC, Nah H, et al. A hybrid nanoparticle probe for dualmodality positron emission tomography and magnetic resonance imaging. Angew Chem Int Ed Engl. 2008;47(33):6259-6262.
83. Uppal R, Catana C, Ay I, Benner T, Sorensen AG, Caravan P. Bimodal thrombus imaging: simultaneous PET/MR imaging with a fibrintargeted dual PET/MR probe - feasibility study in rat model. Radiology. 2011;258(3):812-820.
84. Zhu H, Zhao J, Lin X, Hong Y, Li C, Yang Z. Design, synthesis and evaluation of dual-modality glyco-nanoparticles for tumor imaging. Molecules. 2013;18(6):6425-6438.
85. Sun IC, Eun DK, Koo H, et al. Tumor-targeting gold particles for dual computed tomography/optical cancer imaging. Angew Chem Int Ed Eng. 2011;123(40):9520-9523.
86. Zhou Z, Zhang C, Qian Q, et al. Folic acid-conjugated silica capped gold nanoclusters for targeted fluorescence/X-ray computed tomography imaging. J Nanobiotechnology. 2013;11(1):17.
87. 4: Yb,Tm for lymphatic imaging in vivo by real-time upconversion luminescence imaging under ambient light and high-resolution X-ray CT. Theranostics. 2013;3(5):346-353.
88. Hwang DW, Ko HY, Lee JH, et al. A nucleolin-targeted multimodal nanoparticle imaging probe for tracking cancer cells using an aptamer. J Nucl Med. 2010;51(1):98-105.
89. Xie J, Chen K, Huang J, et al. PET/NIRF/MRI triple functional iron oxide nanoparticles. Biomaterials. 2010;31(11):3016-3022.
90. John R, Nguyen F, Kolbeck K, et al. Targeted multifunctional multimodal protein-shell microspheres as cancer imaging contrast agents. Mol Imaging Biol. 2012;14(1):17-24.
91. Kim J, Arifin DR, Muja N, et al. Multifunctional capsule-in-capsules for immunoprotection and trimodal imaging. Angew Chem Int Ed Engl. 2011;50(10):2317-2321.
92. 3+ nanophosphors for upconversion luminescence, MR, and PET imaging of tumor angiogenesis. J Nucl Med. 2013;54(1):96-103.
93. Boerman OC, Oyen WJ. Multimodality probes: amphibian cars for molecular imaging. J Nucl Med. 2008;49(8):1213-1214.